检索结果-南通市图书馆

Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2019年第5期8卷 569-571页

作者： hyun Yang Pil Soo Sung Jaejun Lee Seung Kew Yoon Eun Sun Jung Cheon-Soo Park si hyun bae The Catholic University Liver Research Center College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea Department of Internal medicine College of MedicineEunpyeong St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea Department of Internal Medicine College of MedicineSeoul St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea Department of Hospital Pathology College of MedicineEunpyeong St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea Department of Surgery College of MedicineEunpyeong St.Mary’s HospitalThe Catholic University of KoreaSeoulRepublic of Korea

A recent report demonstrated immune heterogeneityof hepatocellular carcinoma(HCC)(1).The objectiveresponse rates of sorafenib-treated global and Asian patientsby nivolumab,the monoclonal antibody to programmedcell dea... 详细信息

关键词： hepatocellular nivolumab surgery

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第43期18卷 6277-6283页

作者： Myeong Jun Song Do Seon Song Hee Yeon Kim Sun Hong Yoo si hyun bae Jong Young Choi Seung Kew Yoon Yong-Han Paik June Sung Lee hyun Woong Lee hyung Joon Kim Departments of Internal Medicine College of Medicine The Catholic University of Korea Seoul 137-040 South Korea Departments of Internal Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul 135-710 South Korea Departments of Internal Medicine College of Medicine Inje University Ilsan Paik Hospital of The Korea Goyang-si 411-706 South Korea Departments of Internal Medicine College of Medicine The Chung-Ang University of Korea Seoul 156-755 South Korea

AIM:To evaluate the durability in hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients who discontinued antiviral treatment. METHODS:A total of 48 HBeAg positive chronic hepatitis B patients who were administered nucleoside analogues and maintained virological response for ≥ 6 mo [hepatitis B virus (HBV) DNA sion] before cessation of treatment were enrolled between February 2007 and January 2010. The criteria for the cessation of the antiviral treatment were defined as follows:(1) achievement of virological response; and (2) duration of consolidation therapy (≥ 6 mo). After treatment cessation, the patients were followed up at 3-6 mo intervals. The primary endpoint was serologic and virologic recurrence rates after withdrawal of antiviral treatment. Serologic recurrence was defined as reappearance of HBeAg positivity after HBeAg seroconversion. Virologic recurrence was defined as an increase in HBV-DNA level > 104 copies/mL after HBeAg seroconversion with previously undetectable HBV-DNA level. RESULTS:During the median follow-up period of 18.2 mo (range:5.1-47.5 mo) after cessation of antiviral treatment, the cumulative serological recurrence rate was 15 % at 12 mo. The median duration between the cessation of antiviral treatment and serologic recurrence was 7.2 mo (range:1.2-10.9 mo). Of the 48 patients with HBeAg positive chronic hepatitis, 20 (41.6%) showed virological recurrence. The cumulative virologic recurrence rates at 12 mo after discontinuing the antiviral agent were 41%. The median duration between off-treatment and virologic recurrence was 7.6 mo (range:4.3-27.1 mo). The mean age of the virological recurrence group was older than that of the non-recurrence group (46.7 ± 12.1 years vs 38.8 ± 12.7 years, respectively; P = 0.022). Age (> 40 years) and the duration of consolidation treatment (≥ 15 mo) were significant predictive factors for offtreatment durability in the multivariate analysis [P = 0.049, relative risk (RR) 0.31, 95% CI (0.096-0.998) and

关键词：慢性乙型肝炎抗病毒治疗 HBeAg 乙型肝炎病毒耐久性阳性 DNA水平反应

Selective COX-2 inhibitor,NS-398,suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2007年第8期13卷 1175-1181页

作者： Ji Yeon baek Wonhee Hur Jin Sang Wang si hyun bae Seung Kew Yoon Department of Internal Medicine College of Medicine The Catholic University of Korea 505 Banpo-dong Seocho-gu 137-701 Seoul Korea WHO Collaborating Center for Reference and Research on Viral Hepatitis The Catholic University of Korea 505 Banpo-dong Seocho-gu 137-701 Seoul Korea

AIM: To investigate the growth inhibitory mechanism of NS-398, a selective cyclooxygenase-2 (COX-2) inhibitor, in two hepatocellular carcinoma (HCC) cell lines (HepG2 and Huh7). METHODS: HepG2 and Huh7 cells were treated with NS-398. Its effects on cell viability, cell proliferation, cell cycles, and gene expression were respectively evaluated by water-soluble tetrazolium salt (WST-1) assay, 4’-6-diamidino-2-phenylindole (DAPI) staining, flow cytometer analysis, and Western blotting, with dimethyl sulfoxide (DMSO) as positive control. RESULTS: NS-398 showed dose- and time-dependent growth-inhibitory effects on the two cell lines. Proliferating cell nuclear antigen (PCNA) expressions in HepG2 and Huh7 cells, particularly in Huh7 cells were inhibited in a time- and dose-independent manner. NS-398 caused cell cycle arrest in the G1 phase with cell accumulation in the sub-G1 phase in HepG2 and Huh7 cell lines. No evidence of apoptosis was observed in two cell lines. CONCLUsiON: NS-398 reduces cell proliferation by inducing cell cycle arrest in HepG2 and Huh7 cell lines, and COX-2 inhibitors may have potent chemoprevention effects on human hepatocellular carcinoma.

关键词：选择性COX-2抑制剂 NS-398 肝细胞癌细胞系细胞周期阻滞细胞增殖

Predictive value of ^(18)F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第25期18卷 3215-3222页

作者： Myeong Jun Song si hyun bae Ie Ryung Yoo Chung-Hwa Park Jeong Won Jang Ho Jong Chun Byung Gil Choi Hae Giu Lee Jong Young Choi Seung Kew Yoon Department of Internal Medicine College of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Nuclear Medicine College of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Radiology College of MedicineThe Catholic University of KoreaSeoul 137-040South Korea

Myeong Jun Song,si hyun bae,Chung-Hwa Park,Jeong Won Jang,Jong Young Choi,Seung Kew Yoon,Department of Internal Medicine,College of Medicine,The Catholic University of Korea,Seoul 137-040,South Korea Ie Ryung Yoo,Department of Nuclear,Medicine College of Medicine,The Catholic University of Korea,Seoul 137-040,South Korea Ho Jong Chun,Byung Gil Choi,Hae Giu Lee,Department of Radiology,College of Medicine,The Catholic University of Korea,Seoul 137-040,South

关键词：肝癌预测显像计算机断层扫描应用价值评价标准改性反应

Severe thrombocytopenia before liver transplantation is associated with delayed recovery of thrombocytopenia regardless of donor type

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2008年第37期14卷 5723-5729页

作者： Jae Hyuck Chang Jong Young Choi hyun Young Woo Jung hyun Kwon Chan Ran You si hyun bae Seung Kew Yoon Myung-Gyu Choi In-sik Chung Dong Goo Kim Department of Internal Medicine College of Medicine the Catholic University of Korea505 Banpo-Dong Seocho-Gu Seoul 137-040 Korea Department of Surgery College of Medicine the Catholic University of Korea505 Banpo-Dong Seocho-Gu Seoul 137-040 Korea

AIM: To compare the recovery of thrombocytopenia and splenomegaly during long-term follow-up after liver transplantation in patients receiving a living donor transplant or a cadaveric donor transplant. METHODS: This was a retrospective cohort study of 216 consecutive liver transplant patients who survived for > 6 mo after transplantation; 169 received a liver transplant from a living donor and 47 from a cadaveric donor. The platelet counts or spleen volumes were examined before transplant, 1, 6, and 12 mo after transplant, and then annually until 5 years after transplant. RESULTS: The mean follow-up period was 49 mo (range, 21-66). Platelet counts increased continu-ously for 5 years after orthotopic liver transplant. The restoration of platelet counts after transplant was sig-nificantly slower in patients with severe pretransplant thrombocytopenia (significantly affect the recovery of platelet count and spleen vol-ume in either patient group. In multivariate analysis, pretransplant severe thrombocytopenia (sis site. CONCLUsiON: Our study suggests that severe throm-bocytopenia before transplant is closely associated with delayed recovery of platelet count after transplant and donor type did not affect the recovery of throm-bocytopenia. The reappearance of thrombocytopenia after transplant should be considered a possible indica-tor of flow disturbance in the portal vein.

关键词：肝移植血小板减少症脾肿大并发症

Epirubicin,Cisplatin,5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2014年第1期20卷 235-241页

作者： Ji Eun Lee si hyun bae Jong Young Choi Seung Kew Yoon Young Kyoung You Myung Ah Lee Division of Medical Oncology Hepato-Biliary-Pancreatic Cancer CenterCancer Research Institute Seoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Internal Medicine Hepato-Biliary-Pancreatic Cancer CenterCancer Research InstituteSeoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Division of Hepatology Hepato-Biliary-Pancreatic Cancer CenterCancer Research Institute Seoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Surgery Hepato-Biliary-Pancreatic Cancer CenterCancer Research InstituteSeoul St. Mary’s HospitalCollege of MedicineThe Catholic University of KoreaSeoul 137-040South Korea

AIM:To evaluate the clinical efficacy and safety of epirubicin,cisplatin,and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma(HCC).METHODS:From April 2009 to June 2012,31 patients who were diagnosed with metastatic and progressive HCC after sorafenib treatment were retrospectively reviewed.Patients were treated with the combination of epirubicin(50 mg/m2Ⅳ;day 1),cisplatin(60 mg/m2Ⅳ;day 1),and 5-FU(1000 mg/m2Ⅳ;day 1-3)[Epirubicin,cisplatin,5-FU combination(ECF)],repeated every 4 wk.RESULTS:The overall response rate was 12.9%.Patients who responded to ECF chemotherapy showed a longer overall survival(OS)and time to progression(TTP)relative to those in the non-responder group(OS:20.4 mo vs 4.9 mo,Psive disease(OS:13.4 mo vs 5.3 mo,P=0.003;TTP:9.4 mo vs 2.3 mo,P=0.003).The most common hematologic toxicity was thrombocytopenia(87.2%),and the incidence of grade 3-4 neutropenia was 53.9%.Age older than 60,a stable primary mass,and a good response to chemotherapy were prognostic factors for OS and TTP.CONCLUsiON:This combination cytotoxic chemotherapy can serve as another treatment option after sorafenib failure for the subset of patients with advanced metastatic HCC.

关键词： Hepatocellular carcinoma Sorafenib Epirubicin Cisp

Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2008年第11期14卷 1781-1784页

作者： Soon Woo Nam si hyun bae Seung Woo Lee Yeon Soo Kim Sang Bum Kang Jong Young Choi Se hyun Cho Seung Kew Yoon Joon-Yeol Han Jin Mo Yang Young Suk Lee Division of Gastroenterology and Hepatology Department ofInternal medicineMedical College of the Catholic University ofKoreaDaejeon St.Mary's Hospital#62 Daeheung-dongChung-guDaejeonRepublic of Korea

AIM:To evaluate the efficacy of short-term overlap lamivudine therapy with adefovir in patients with lamivudine-resistant and nave chronic hepatitis B,we compared patients receiving overlap therapy with those receiving adefovir alone. METHODS:Eighty patients who had received lamivudine treatment for various periods and had a lamivudine- resistant liver function abnormality were enrolled.Forty of these patients received adefovir treatment combined with lamivudine treatment for≥2 mo,while the other 40 received adefovir alone.We assessed the levels of hepatitis B virus(HBV)DNA at 0,12 and 48 wk and serum alanine aminotransferase(ALT)levels after 0,12, 24 and 48 wk of adefovir treatment in each group. RESULTS:We found serum ALT became normalized in 72(87.5%)of the 80 patients,and HBV DNA decreased by≥2 log10 copies/mL in 60(75%)of the 80 patients at the end of a 48-wk treatment.HBV DNA levels were not significantly different between the groups.The improvements in serum ALT were also not significantly different between the two groups. CONCLUsiON:These findings suggest short-term overlap lamivudine treatment results in no better virological and biological outcomes than non-overlap adefovir monotherapy.

关键词：慢性乙型肝炎乙肝病毒短期治疗抵抗力

Risk factors of biliary intervention by imaging after livingdonor liver transplantation

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第7期22卷 2342-2348页

作者： Soon Kyu Lee Jong Young Choi Dong Myung Yeo Young Joon Lee Seung Kew Yoon si hyun bae Jeong Won Jang Hee Yeon Kim Dong Goo Kim Young Kyoung You Division of Hepatology Department of Internal MedicineCollege of MedicineThe Catholic University of KoreaSeoul 06591South Korea Department of Radiology College of MedicineThe Catholic University of KoreaSeoul 06591South Korea Department of Surgery College of MedicineThe Catholic University of KoreaSeoul 06591South Korea

AIM:To determine the risk factors of biliary intervention using magnetic resonance cholangiopancreatography(MRCP) after living donor liver transplantation(LDLT).METHODS: We retrospectively enrolled 196 patients who underwent right lobe LDLT between 2006 and 2010 at a single liver transplantation center. Direct duct-to-duct biliary anastomosis was performed in all 196 patients. MRCP images routinely taken 1 mo after LDLT were analyzed to identify risk factors for biliary intervention during follow-up, such as retrograde cholangiopancreatography or percutaneous transhepatic biliary drainage. Two experienced radiologists evaluated the MRCP findings, including the anastomosis site angle on three-dimensional images, the length of the filling defect on maximum intensity projection, bile duct dilatation, biliary stricture, and leakage.RESULTS: Eighty-nine patients underwent biliary intervention during follow-up. The anastomosis site angle [hazard ratio(HR) = 0.48; 95% confidence interval(CI), 0.30-0.75, P sis site(HR = 2.18, 95%CI: 1.41-3.38,P = 0.001), and biliary leakage(HR = 2.52, 95%CI: 1.02-6.20, P = 0.048) on MRCP were identified in the multivariate analysis as significant risk factors for biliary intervention during follow-up. Moreover, a narrower anastomosis site angle(i.e., below the median angle of 113.3°) was associated with earlier biliary intervention(38.5 ± 4.2 mo vs 62. 1 ± 4.1 mo, P sis comparing biliary intervention-free survival according to the anastomosis site angle revealed that lower survival was associated with a narrower anastomosis site angle(36.3% vs 62.0%, P siON: The biliary anastomosis site angle in MRCP after LDLT may be associated with the need for biliary intervention.

关键词： Magnetic resonance cholangiopancreatography Liver transplantation Living donor Biliary intervention Endoscopic retrograde cholangiopancreatography Percutaneous transhepatic biliarydrainage

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第29期19卷 4679-4688页

作者： Do Seon Song si hyun bae Myeong Jun Song Sung Won Lee Hee Yeon Kim Young Joon Lee Jung Suk Oh Ho Jong Chun Hae Giu Lee Jong Young Choi Seung Kew Yoon Department of Internal Medicine College of Medicine The Catholic University of Korea Seoul 137-040 South Korea Department of Radiology College of Medicine The Catholic University of Korea Seoul 137-040 South Korea

AIM: To evaluate the prognostic factors and efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. METHODS: Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port. The epirubicin-cisplatin-5-fluorouracil (ECF) chemotherapeutic regimen consisted of 35 mg/m 2 epirubicin on day 1, 60 mg/m 2 cisplatin for 2 h on day 2, and 500 mg/m 2 5-fluorouracil for 5 h on days 1-3. The treatments were repeated every 3 or 4 wk. RESULTS: Three (6%) of the 50 patients achieved a complete response (CR), 13 (26%) showed partial responses (PR), and 22 (44%) had stable disease (SD).The median survival and time to progression were 7 and 2 mo, respectively. After 2 cycles of HAIC, CR was achieved in 1 patient (2%), PR in 10 patients (20%) and SD in 26 patients (52%). significant pre-treatment prognostic factors were a tumor volume of significant prognostic factors. Adverse events were tolerable and successfully managed. CONCLUsiON: HAIC may be an effective treatment modality for advanced HCC with PVTT in patients with tumors < 400 cm 3 and good prognostic factors.

关键词： Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Portal vein tumor thrombosis